Completed PHASE2 INTERVENTIONAL 2-arm NCT00810667

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

A Randomised, Double-blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia

Sponsor: H. Lundbeck A/S

Conditions Cognition Schizophrenia

Interventions Lu AE58054 Placebo

Updated 7 times since 2017 Last updated: Nov 7, 2016 Started: Nov 30, 2008 Primary completion: Jan 31, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cognition and Schizophrenia, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bełchatów, Poland , Bialystok, Poland , Bordeaux, France , Brescia, Italy , Brumath, France , Chiang Mai, Thailand , Dresden, Germany , Hong Kong, Hong Kong , Hualien City, Taiwan , Keelung, Taiwan and 13 more locations